A Trial to Investigate the Safety and the Pharmacokinetic, Pharmacodynamic Characteristics of Two BioChaperone® Glucagon Formulations Compared to Marketed GlucaGen® in Subjects With T1DM

Inclusion Criteria: * Male or female patients aged between 18 and 64 years (both inclusive) * Type 1 diabetes mellitus (as diagnosed clinically) ≥ 12 months prior to the screening visit * Treated with daily insulin for T1DM ≥ 12 months prior to the screening visit * Stable insulin treatment at least 3 months prior to the screening visit * Stable disease with HbA1c \<9.0 % * C peptide \<=0.30 nmol/L * Body mass index (BMI) \< 30.0 kg/m2 Exclusion Criteria: * Type 2 Diabetes mellitus * Previous participation in this trial. Participation is defined as being randomised * Receipt of any medicinal product in clinical development within 60 days prior to this trial * Clinically significant abnormal haematology, biochemistry, urinalysis, or coagulation screening tests, as judged by the Investigator considering the underlying disease * Known or suspected hypersensitivity to the trial products or related products * Severe hypoglycaemic events within one month prior to screening, as judged by the investigator * Recent administration of glucagon (within 3 months prior to Screening) * Clinically relevant diabetic complications as judged by the investigator * Women of child bearing potential not willing to use contraceptive methods